非小细胞肺癌质子与光子放化疗后心血管亚结构剂量与心脏事件
回顾性匹配26例放化疗后发生心脏事件与26例未发生事件的局部晚期非小细胞肺癌患者,比较心脏及10个心血管亚结构剂量。结果显示两组间心脏及各亚结构剂量均无显著差异(P均>.05),质子治疗组平均心脏剂量及左心室、右心室、左前降支剂量显著低于光子治疗组。
要点
- 放化疗后发生与未发生心脏事件患者间,心脏及各心血管亚结构剂量均无显著差异(P均>.05)。
- 质子治疗组平均心脏剂量显著低于光子治疗组(P=.032)。
- 质子治疗组左心室、右心室、左前降支剂量(多项指标)显著更低(P=.0004、P<.0001、P=.0002)。
核心结论
- 质子治疗可能显著降低心血管亚结构剂量,但与光子治疗相比对心脏事件的影响尚需进一步研究。
- 放化疗后发生与未发生心脏事件患者间,心脏剂量及各心血管亚结构剂量均无显著差异。
研究设计与样本
- 回顾性匹配研究,纳入26例局部晚期非小细胞肺癌放化疗后发生心脏事件患者,按放疗技术(质子vs光子)、年龄、性别及心血管合并症匹配26例未发生心脏事件患者。
- 对每例患者手工勾画全心脏及10个心血管亚结构,比较发生与未发生心脏事件组间及质子与光子组间剂量学差异。
主要发现
- 发生与未发生心脏事件组间,心脏及各心血管亚结构剂量均无显著差异(P均>.05)。
- 质子治疗组平均心脏剂量显著低于光子治疗组(P=.032)。
- 质子治疗组左心室剂量显著低于光子组(P=.0004)。
- 质子治疗组右心室剂量显著低于光子组(P<.0001)。
- 质子治疗组左前降支剂量显著低于光子组(P=.0002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究评估心血管亚结构剂量与治疗后心脏事件之间的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation therapy (RT) plays a critical role in treating locally advanced non-small cell lung cancer but has been associated with deleterious cardiac effects. We hypothesized that RT dose to certain cardiovascular substructures may be higher among those who experience post-chemoradiation (CRT) cardiac events, and that dose to specific substructures-the great vessels, atria, ventricles, and left anterior descending coronary artery-may be lower with proton- versus photon-based RT. METHODS AND MATERIALS: In this retrospective review, we selected 26 patients who experienced cardiac events after CRT for locally advanced non-small cell lung cancer and matched them to 26 patients who did not experience cardiac events after CRT. Matching was done based on RT technique (protons vs photons), age, sex, and cardiovascular comorbidity. For each patient, the whole heart and 10 cardiovascular substructures on the RT planning computerized tomography scan were manually contoured. Dosimetric comparisons were made between those who did and did not experience cardiac events and between the proton and photon groups. RESULTS: There was no significant difference in heart or any cardiovascular substructure dose between those patients who experienced post-treatment cardiac events and those who did not (P > .05 for all). The mean heart dose in the patients receiving proton therapy was significantly lower than the mean heart dose in the patients receiving photon therapy (P = .032). The left ventricle, right ventricle, and the left anterior descending artery also had significantly lower doses (by multiple measures) when treated with protons (P = .0004, P < .0001, and P = .0002, respectively). CONCLUSIONS: Proton therapy may have a significant effect on decreasing dose to individual cardiovascular substructures compared with photon therapy. There was no significant difference in heart dose or dose to any cardiovascular substructure between patients who did and did not experience post-treatment cardiac events. Further research should be done to assess the association between cardiovascular substructure dose and post-treatment cardiac events.
引用
- Natarajan J, Yegya-Raman N, Kegelman TP, et al. Cardiovascular Substructure Dose and Cardiac Events following Proton- and Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer. Adv Radiat Oncol. 2023. PMID: 37408679. doi:10.1016/j.adro.2023.101235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。